CD22 and B-cell non-Hodgkin lymphoma: InO at 0.8 mg/m2 combined with full dose of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) was reported safe and effective for CD22+ R/R B cell NHL in a phase I trial (NCT01055496).